

---

# TRANSGENE Patents

Matching "TRANSGENE" by Owner.

**IPMonitor**  
Patents

---

# Contents

|  |   |
|--|---|
| Alerts .....   | 3 |
| "TRANSGENE" .....  | 3 |
| Terms and Conditions .....                               | 5 |
| General .....  | 5 |
| Disclaimer of warranty and limitation of liability ..... | 5 |
| Copyright .....  | 5 |
| Arbitration .....  | 5 |

# Alerts

## "TRANSGENE"

49 results matching "'TRANSGENE'" by Owner.

| Number                     | Title   | Owner   |
|----------------------------|---|---|
| <a href="#">2002301878</a> | Chimeric promoters for controlling expression in muscle cells   | Transgene S.A.  |
| <a href="#">2002234673</a> | Biological organism for preparing pharmaceutical compositions for treating mammals  | TRANSGENE S.A.  |
| <a href="#">2002342319</a> | Complexes for transferring substances if interest into a cell   | TRANSGENE S.A.  |
| <a href="#">2002344190</a> | Adenovirus protein IX, Its domains involved in capsid assembly, transcriptional activity and nuclear reorganization   | Transgene S.A.  |
| <a href="#">2002301344</a> | Use of a nuclease inhibitor or interleukin-10 (IL-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy | Transgene S.A. ; Association Francais contre les Myopathies |
| <a href="#">2002353426</a> | Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell  | TRANSGENE S.A.  |
| <a href="#">2002247723</a> | USE OF NON-COMPLEXING PEPTIDES FOR THE PREPARATION OF A COMPOSITION FOR TRANSFECTION OF A POLYNUCLEOTIDE INTO A CELL AND COMPOSITIONS USEFUL IN GENE THERAPY  | TRANSGENE S.A.  |
| <a href="#">2001270614</a> | Chimeric promoters for controlling expression in smooth muscle cells  | Transgene S.A.  |
| <a href="#">2003206815</a> | ADENOVIRAL VECTORS FOR MODULATING THE CELLULAR ACTIVITIES ASSOCIATED WITH PODS  | TRANSGENE S.A.  |
| <a href="#">2003216778</a> | Antisense compounds directed against human CSF-1  | TRANSGENE ; INSTITUT CURIE                                  |
| <a href="#">2003215871</a> | Expression cassette for persistence of expression of a gene of interest in muscle cells   | TRANSGENE S.A.  |
| <a href="#">2003246073</a> | Mutant having uracil phosphoribosyl transferase activity  | Transgene   |
| <a href="#">2003246359</a> | SERUM-FREE CELL CULTURE MEDIA AND METHODS FOR PRODUCING VIRAL STOCKS  | TRANSGENE S.A.  |
| <a href="#">2003247128</a> | MODIFIED ADENOVIRAL FIBER ABLATED IN BINDING TO GLYCOSAMINOGLYCAN OR SIALIC ACIDCONTAINING CELLULAR RECEPTORS   | TRANSGENE S.A.  |
| <a href="#">2003250872</a> | SERUM-FREE CELL CULTURE MEDIA AND METHODS FOR PRODUCING HIGH DENSITY CELL CULTURE   | TRANSGENE S.A.  |
| <a href="#">2004263274</a> | Novel multifunctional cytokines   | Transgene S.A.  |
| <a href="#">2004257935</a> | Polypeptide having an improved cytosine deaminase activity  | Transgene S.A.  |

| Number                     | Title  | Owner  |
|----------------------------|--|--|
| <a href="#">2004247457</a> | Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5b of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use | Institut National De La Sante Et De La Recherche Medicale ; Transgene SA |
| <a href="#">2005300248</a> | Kit of parts designed for implementing an antitumoral or antiviral treatment in a mammal   | Transgene S.A.   |
| <a href="#">2007204024</a> | Avian telomerase reverse transcriptase   | Transgene S.A.   |
| <a href="#">2007222580</a> | Hepatitis C virus non structural fusion protein  | Transgene S.A.   |
| <a href="#">2007241405</a> | HPV-18-based papillomavirus vaccine  | Transgene S.A.   |
| <a href="#">2007241406</a> | HPV-16-based papillomavirus vaccine  | Transgene S.A.   |
| <a href="#">2007263280</a> | Process for producing poxviruses and poxvirus compositions   | Transgene S.A.   |
| <a href="#">2007263355</a> | Use of PPD for the adjuvantation of a nucleic acid vaccine   | Transgene S.A.   |
| <a href="#">2007263281</a> | Recombinant viral vaccine  | Transgene S.A.   |
| <a href="#">2007327807</a> | Means and method for raising improved immune response  | Transgene S.A.   |
| <a href="#">2008209759</a> | Papillomavirus E2 polypeptide used for vaccination   | Transgene S.A.   |
| <a href="#">2008228450</a> | Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5b of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use | Transgene SA   |
| <a href="#">2009222623</a> | Novel multifunctional cytokines  | Transgene S.A.   |
| <a href="#">2008250520</a> | Vectors for multiple gene expression   | Transgene S.A.   |
| <a href="#">2008250521</a> | Signaling peptides   | Transgene S.A.   |
| <a href="#">2009251215</a> | Polypeptide having an improved cytosine deaminase activity   | Transgene S.A.   |
| <a href="#">2010200422</a> | Novel multifunctional cytokines  | Transgene S.A.   |
| <a href="#">2008270317</a> | Immortalized avian cell lines  | Transgene S.A.   |
| <a href="#">2008328257</a> | Poxviral oncolytic vectors   | Transgene SA   |
| <a href="#">2008328258</a> | Poxviral oncolytic vectors   | Transgene SA   |
| <a href="#">2009224955</a> | Antibody against the CSF-1 R   | Transgene S.A.   |
| <a href="#">2009259699</a> | Biomarker for selecting patients and related methods   | Transgene SA   |
| <a href="#">2010257416</a> | Antibody against the CSF-1R  | Transgene S.A.   |
| <a href="#">2010205717</a> | Use of a Saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation  | Transgene SA   |
| <a href="#">2010206195</a> | Soluble ICAM-1 as biomarker for prediction of therapeutic response   | Transgene SA   |
| <a href="#">2010227611</a> | Biomarker for monitoring patients  | Transgene SA   |
| <a href="#">2010237215</a> | Biomarker for monitoring patients  | Transgene SA   |
| <a href="#">2010270313</a> | Biomarker for selecting patients and related methods   | Transgene SA   |
| <a href="#">2010247371</a> | Method for orthopoxvirus production and purification   | Transgene SA   |
| <a href="#">2010247374</a> | Immortalized avian cell lines and use thereof  | Transgene SA   |
| <a href="#">2010280710</a> | Composition for treating HBV infection   | Transgene SA   |
| <a href="#">2010275764</a> | Enzymatic composition for the digestion of chicken embryos   | Transgene SA   |

---

# Terms and Conditions

## General

The information provided in this report is not in the nature of legal or other professional advice.

The information provided in this report is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals regarding any information in this report.

Patents, patent applications, trademarks and trademark applications shown as lapsed or ceased may be restored at a later date.

## Disclaimer of warranty and limitation of liability

Neither IPMonitor, its affiliates nor any of their respective employees, agents, third party content providers or licensors warrant that the information contained in this report is error free; nor do they make any warranty as to the accuracy, reliability or content of any information in this report.

This report is provided on an "as is" basis; to the maximum extent permitted by law, IPMonitor disclaims all representations and warranties, express or implied, with respect to any information contained in this report. In addition, IPMonitor does not represent or warrant that the information contained in this report is accurate, complete or current.

This disclaimer of liability applies to any damages or injury caused by any failure of performance, error, omission, interruption, deletion, defect, delay in operation or transmission, computer virus, communication line failure, theft or destruction or unauthorized access to, alteration of, or use of record, whether for breach of contract, tortious behavior, negligence, or under any other cause of action.

## Copyright

The content of this report may be protected by copyright laws and treaties around the world and all rights relating to the same are reserved. Any paper or digital copies of this report are not to be modified or any illustrations or any graphics used separately from any accompanying text.

## Arbitration

Any dispute or difference whatsoever arising out of or in connection with this report shall be submitted to arbitration in accordance with, and subject to, The Institute of Arbitrators & Mediators Australia Rules for the Conduct of Commercial Arbitrations.

IPMonitor reserves the right to update the Terms and Conditions at any time without notice. Please see the full Terms and Conditions at [www.IPMonitor.com.au/trademarks/info/terms](http://www.IPMonitor.com.au/trademarks/info/terms)